Hypertrophic Cardiomyopathy Quiz

Hypertrophic Cardiomyopathy (HCM): Core Concepts for Clinical Review

Hypertrophic Cardiomyopathy (HCM) is a complex genetic cardiac disorder characterized by unexplained myocardial hypertrophy. A solid grasp of its pathophysiology, diagnosis, and management is essential for clinical practice and board examinations.

Genetic and Pathophysiological Basis

HCM is most commonly an autosomal dominant disorder resulting from mutations in genes that encode for cardiac sarcomere proteins. This genetic defect leads to myocyte disarray, hypertrophy, and fibrosis, which are the histological hallmarks of the disease.

Hallmarks of LVOT Obstruction

A key feature in about two-thirds of patients is dynamic left ventricular outflow tract (LVOT) obstruction. This is primarily caused by two factors working in concert: asymmetric septal hypertrophy and systolic anterior motion (SAM) of the mitral valve, where the mitral leaflet is pulled into the LVOT during systole.

Clinical Presentation and Symptoms

The clinical spectrum of HCM is broad, ranging from asymptomatic individuals to those with severe heart failure or sudden cardiac death (SCD). Understanding the common symptoms is key for initial suspicion.

• Dyspnea: The most common symptom, often exertional, due to diastolic dysfunction and elevated filling pressures.
• Angina: Chest pain can occur even with normal coronary arteries due to myocardial oxygen supply-demand mismatch.
• Syncope or Presyncope: Often exertional, can be caused by LVOT obstruction, arrhythmias, or abnormal blood pressure response.
• Palpitations: Commonly due to atrial fibrillation or ventricular arrhythmias.
• Fatigue and Exercise Intolerance: A general symptom related to impaired cardiac output.

Diagnostic Imaging: Echocardiography Essentials

Echocardiography is the cornerstone for diagnosing HCM. Key findings include an unexplained maximal wall thickness of ≥15 mm in any myocardial segment. It also assesses for SAM, LVOT gradients (at rest and with provocation), diastolic function, and left atrial size.

ECG Findings in HCM

While not diagnostic, the ECG is abnormal in over 90% of HCM patients. Common findings include signs of left ventricular hypertrophy (LVH), prominent Q waves (especially in inferior/lateral leads), and deeply inverted T waves in the precordial leads, which can mimic ischemia.

Risk Stratification for Sudden Cardiac Death (SCD)

Identifying patients at high risk for SCD is a critical component of management, as an implantable cardioverter-defibrillator (ICD) can be life-saving. Major risk factors are often remembered as a core set.

• Massive LV hypertrophy (wall thickness ≥ 30 mm)
• Family history of premature HCM-related SCD
• Recent unexplained syncope
• Nonsustained ventricular tachycardia (NSVT) on Holter monitoring
• Abnormal blood pressure response during exercise (failure to augment or a drop)
• Left ventricular apical aneurysm

Pharmacological Management Strategies

Treatment is aimed at symptom relief. First-line agents are beta-blockers or non-dihydropyridine calcium channel blockers (e.g., verapamil). These drugs improve diastolic filling and can reduce the LVOT gradient. For refractory symptoms, disopyramide may be added.

Differentiating HCM from Athlete’s Heart

This is a common diagnostic challenge. Athlete’s heart typically involves symmetric, modest hypertrophy (usually <15 mm) with a normal or enlarged LV cavity and normal diastolic function. In contrast, HCM usually presents with asymmetric hypertrophy, a non-dilated LV cavity, and evidence of diastolic dysfunction.

Key Takeaways

• HCM is primarily a genetic disorder of the cardiac sarcomere.
• Asymmetric septal hypertrophy and systolic anterior motion (SAM) cause LVOT obstruction.
• Dyspnea on exertion is the most common presenting symptom.
• Echocardiography is the primary tool for diagnosis and assessment.
• Risk stratification for SCD is crucial for determining the need for an ICD.

This content provides a high-level overview for educational purposes. A deep understanding of hypertrophic cardiomyopathy requires comprehensive study of current clinical guidelines and research for accurate diagnosis and management.